Mastisan belongs to combination antimicrobial drugs.
Mastisan has a broad-spectrum antibacterial action, caused by the components of the formulation exhibiting synergism against certain microorganisms. The drug is active against Gram-positive and Gram-negative microorganisms (staphylococci, streptococci, proteus, Escherichia coli, salmonella, etc.).
Penicillin belongs to ß-lactam antibiotics.
Mode of action: penicillin eliminates bacteria by suppressing the functional activity of bacterial transpeptidase enzymes involved in peptidoglycan binding, thus interfering with the synthesis of the bacterial cell wall and causing disruption of the osmotic balance and death of bacteria.
Streptomycin refers to aminoglycoside antibiotics. Mode of action: streptomycin eliminates bacteria by violating protein synthesis within a bacterial cell, thus causing a violation in the structure of the cell membrane and the death of bacteria.
Sulfadimidine belongs to sulfonamide antibacterial compounds.
Mode of action: sulfadimidine eliminates bacteria by a competitive antagonism with paraminobenzoic acid, inhibiting dihydropteroate synthetase, and violating the synthesis of tetrahydrofolate acid, required to synthesize purines and pyrimidines.
When administered intracisternally, the active substances of the drug are localized in the tissues of the mammary gland, without being absorbed within the systemic circulation, but with a local bactericidal and bacteriostatic effect. Administered intracisternally, Mastisan allows maintaining therapeutic concentrations of antibiotics in the affected quarter of the udder for 24 hours.